QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Thermo Fisher Scientific

Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met.

Thermo Fisher ends deal agreement for genetic testing firm Qiagen

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

Shares of Qiagen (NYSE:QGEN) decreased 0.51% in after-market trading after the company reported Q2 results.

Qiagen: Q2 Earnings Insights

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN reports full results for second quarter and first half of 2020

QIAGEN Reports Full Results for Second Quarter and First Half Of 2020

Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?

Thermo Fisher Increases Its Buyout Price for Qiagen, but Investors Ask for More

LONDON, Aug. 3, 2020 /PRNewswire/ -- Davidson Kempner continues to increase its position and now holds an 8.0% stake.

Davidson Kempner[1] Now Holds an 8.0% Stake and Finds Qiagen's Standalone Prospects Highly Attractive

QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for QIAGEN (QGEN) This Earnings Season?

LONDON, July 31, 2020 /PRNewswire/ -- To: Dr. Håkan Björklund (Chairman of the Supervisory Board) Stéphane Bancel (Supervisory Board Director) Dr.

Davidson Kempner Letter to Qiagen NV

LONDON, July 28, 2020 /PRNewswire/ -- Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which represent 5.1% of the share capital of QIAGEN N.V. (the "Company") Davidson.

Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN N.V. to Fail

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher

QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher

Co-Diagnostics

NextEra Energy

Ollie's Bargain Outlet Hlds

Boston Beer Company

Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility

Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks

Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.

QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results

Abbott Labs

Teladoc

Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.

3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears

Efficient use of data by artificially intelligent applications has put into the spotlight their urgent need in the healthcare domain.

3 AI Healthcare Stocks to Ride Out the Coronavirus Resurgence

QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.

QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses

Illumina

Labcorp Holdings Inc

Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.

Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus

B&G Foods

SpartanNash

United Therapeutics

Vipshop Hlds

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading  Near 52-Week High That Can Scale Higher

Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.

Diagnostic Testing Remains Crucial in Combatting Coronavirus

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Qiagen (QGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

QIAGEN (QGEN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Earnings Estimates Moving Higher for QIAGEN (QGEN): Time to Buy?

QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.

QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff

QIAGEN (QGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How QIAGEN (QGEN) Stock Stands Out in a Strong Industry?

Repligen

QGEN vs. RGEN: Which Stock Is the Better Value Option?

Regeneron Pharmaceuticals

5 Stocks Trading Near 52-Week High  - That Can Scale Higher

Conagra Brands

DaVita

eBay

General Mills

PEG-based investing can be more rewarding with the addition of a few other relevant parameters amid coronavirus-led market rattle.

News for QIAGEN Stock (QGEN)